Application 212001
- Type
- ANDA
- Sponsor
- CUSTOPHARM INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | GANCICLOVIR SODIUM | GANCICLOVIR SODIUM | INJECTABLE;INJECTION | EQ 500MG BASE/VIAL | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A212001-001 | GANCICLOVIR SODIUM | GANCICLOVIR SODIUM | EQ 500MG BASE/VIAL | INJECTABLE / INJECTION | 2019-06-20 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A212001-001 | GANCICLOVIR SODIUM | EQ 500MG BASE/VIAL | INJECTABLE / INJECTION | 2019-06-20 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Ganciclovir | GANCICLOVIR SODIUM | Fresenius Kabi USA, LLC | b47f5d1c-36b8-49b6-a410-3b3f4661dde7 | 2026-01-09 | Boxed warning, Warnings, Adverse reactions | GANCICLOVIR SODIUM |
| Ganciclovir | GANCICLOVIR SODIUM | Fresenius Kabi USA, LLC | 35addab5-09db-4f8a-9c69-6fbce33ecc37 | 2026-01-09 | Boxed warning, Warnings, Adverse reactions | GANCICLOVIR SODIUM |
| Ganciclovir | GANCICLOVIR SODIUM | Hikma Pharmaceuticals USA Inc. | 4f8219ca-6780-4131-8962-9c3fdd0a84dd | 2025-02-07 | Boxed warning, Warnings, Adverse reactions | GANCICLOVIR SODIUM |
| ganciclovir | GANCICLOVIR SODIUM | Slate Run Pharmaceuticals, LLC | eb100366-2a64-4742-af11-6177a8a494c8 | 2025-01-22 | Boxed warning, Warnings, Adverse reactions | GANCICLOVIR SODIUM |
| ganciclovir sodium | GANCICLOVIR SODIUM | Slate Run Pharmaceuticals, LLC | cd293b9d-b573-4656-8574-19d7db870a9b | 2025-01-02 | Boxed warning, Warnings, Adverse reactions | ganciclovir sodium GANCICLOVIR SODIUM |
| Ganciclovir | GANCICLOVIR SODIUM | Pharmascience Inc. | 3059c2da-d4a7-4aea-828c-20e671cb875c | 2022-12-21 | Boxed warning, Warnings, Adverse reactions | GANCICLOVIR SODIUM |
| ganciclovir | GANCICLOVIR SODIUM | Sagent Pharmaceuticals | 993151ed-cea7-49a7-a967-fac3e9b3c85f | 2020-11-30 | Boxed warning, Warnings, Adverse reactions | GANCICLOVIR SODIUM |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 24201-500 | Ganciclovir | Ganciclovir | Leucadia Pharmaceuticals | ANDA | Current |